相关实验视频

Updated: May 23, 2025

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

索利菲纳对膀过活性的有效性和安全性:最新的系统性审查和元分析

I Gede Yogi Prema Ananda¹, Radika Naufal Hadi Surya², Prima Ardiansah Surya³

¹Department of Urology, Klungkung General Hospital, Klungkung, Bali, Indonesia.

|March 7, 2025

概括

索利芬素有效地治疗过度活动的膀 (OAB) 症状,如急性和失禁. 然而,与安慰剂相比,服用索利费纳的患者经历的不良事件 (AEs) 更多.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

过度活动的膀 (OAB) 是一种慢性疾病,其特点是尿急,有或没有失禁.
索利芬氨酸是一种抗糖剂,是OAB的关键治疗方法,因为它对膀受体有选择性的作用.
虽然有效,但了解索利费纳的安全性和疗效概况需要持续的研究和数据合成.

研究的目的:

系统地审查和元分析索利费纳在治疗过活性膀 (OAB) 中的疗效和安全性.
提供对索利菲纳对关键OAB症状和相关不良事件的影响的最新评估.

主要方法:

遵守PRISMA 2020指南和PROSPERO注册 (CRD42023445318) 的要求.
在PubMed,ScienceDirect和Scopus数据库中进行全面的文献搜索,截至2023年7月.
使用Review Manager版本 5.4.4 的数据进行元分析.

主要成果:

与安慰剂相比,索利菲纳显著减少了紧急事件 (MD = -1.09),失禁事件 (MD = -0.56),排尿频率 (MD = -1.01) 和夜事件 (MD = -0.13).
接受索利费纳治疗的患者24小时尿量显著增加 (MD = 26.88).
在solifenacin组 (MD = 1.75) 和安慰剂组中观察到显著更高的不良事件 (AE) 发生率.

结论:

索利费纳在改善过度活动膀的核心症状方面表现出显著的有效性,包括急性,失禁和频率.
索利费纳的使用与不良事件的统计显著增加有关.
临床医生应仔细权衡治疗效益与潜在的不良事件的治疗效益,在处方索利菲纳用于OAB管理.

关键词:

失禁失禁是一种失禁.过度活动的膀无效的无效的无效的无效的这就是所谓的solifenacin.紧急情况紧急情况

更多相关视频

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation

Author Spotlight: Advanced Treatment of Seminal Duct Blockage Employing Endoscopy-Mediated Semen Channel Refluviation

Published on: December 8, 2023

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...